HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

bimatoprost (Lumigan)

Subscribe to New Research on bimatoprost

an ocular hypotensive agent comparable with travoprost; used to reduce Ocular Hypertension to prevent Glaucoma

Also Known As:

Lumigan; AGN 192024; Allergan brand of bimatoprost; Pharm-Allergan brand of bimatoprost; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-

Networked: 320 relevant articles (61 outcomes, 86 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Woodward, David F: 8 articles (08/2015 - 03/2004)
2.	Whitcup, Scott M: 7 articles (05/2012 - 10/2002)
3.	Hollander, David A: 6 articles (01/2014 - 09/2008)
4.	Noecker, Robert J: 6 articles (04/2008 - 03/2003)
5.	Simonyi, Susan: 5 articles (09/2015 - 07/2009)
6.	Fagien, Steven: 5 articles (04/2015 - 01/2010)
7.	Schiffman, Rhett M: 5 articles (07/2014 - 01/2010)
8.	Walt, John G: 5 articles (08/2013 - 03/2004)
9.	Katz, L Jay: 5 articles (04/2012 - 03/2004)
10.	Batoosingh, Amy L: 5 articles (08/2010 - 01/2003)

Related Diseases

1.	Ocular Hypertension (Glaucoma, Suspect) 08/01/2015 - "Although topical application of bimatoprost, a structural analog of prostaglandin F2α ethanolamide (PGF2α-EA), is currently a first-line treatment for ocular hypertension, the endogenous production of prostamides and their biochemical precursors in corneal tissue has not yet been reported. " 02/01/2007 - "Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension." 01/01/2014 - "Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients." 09/01/2005 - "The authors concluded that bimatoprost is an effective, well-tolerated treatment for lowering intraocular pressure in Thai patients with open-angle glaucoma or ocular hypertension." 11/01/2004 - "In an open-label 12-week study, the safety and efficacy of bimatoprost 0.03% was evaluated in 55 patients with open-angle glaucoma or ocular hypertension inadequately controlled by topical beta-blocker monotherapy. "
2.	Glaucoma 07/01/2009 - "Bimatoprost was effective and safe in lowering IOP both in open angle and pseudoexfoliative glaucoma, achieving target pressure in most patients. " 03/01/2004 - "Bimatoprost is a pharmacologically unique and highly efficacious anti-glaucoma agent. " 09/01/2013 - "Estimate the long-term direct medical costs and clinical consequences of improved adherence with bimatoprost 0.01% compared to bimatoprost 0.03% in the treatment of glaucoma. " 04/01/2014 - "Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients." 01/01/2009 - "Irrespective of the pharmacology of bimatoprost and the prostamides in general, further studies are needed to determine the biological role and biochemical pathology of prostamides in the human eye, particularly in glaucoma. "
3.	Open-Angle Glaucoma (Glaucoma, Open Angle) 11/01/2009 - "Pharmacoeconomic data indicate that bimatoprost is cost effective in the treatment of open-angle glaucoma." 07/01/2009 - "A 12-week study evaluating the efficacy of bimatoprost 0.03% in patients with pseudoexfoliative and open-angle glaucoma." 08/01/2007 - "Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year study." 05/01/2005 - "This study indicates that the intraocular pressures are lowered to a statistically similar amount with DTFC compared to bimatoprost in open-angle glaucoma and ocular hypertensive patients." 10/01/2004 - "A drug utilization trial was performed to investigate acute versus short-term effects after switching or adding bimatoprost in open-angle glaucoma patients over a 3- month observation period. "
4.	Hyperemia 04/01/2014 - "All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (P < 0.05) and in comparison with bimatoprost 0.03% (P < 0.05). " 04/01/2010 - "Bimatoprost 0.01% was equivalent to bimatoprost 0.03% in lowering IOP throughout 12 months of treatment and demonstrated improved tolerability, including less frequent and severe conjunctival hyperemia. " 01/01/2012 - "This real-world, observational study found that bimatoprost 0.01% instilled once daily reduced IOP by a mean of 30% from baseline without moderate or severe ocular hyperemia in 93% of treatment-naïve subjects with POAG or OHT." 01/01/2010 - "Bimatoprost 0.01% was noninferior to vehicle with respect to conjunctival hyperemia in this study population. " 01/01/2005 - "These studies suggest that conjunctival hyperemia, a side effect of bimatoprost treatment, results from non-inflammatory, pharmacologically based vasodilatation."
5.	Low Tension Glaucoma 01/01/2014 - "Bimatoprost 0.03% single treatment was effective in reducing the IOP at least during the 3 years of treatment, but visual field performance worsened by 3.0%-12.1% in patients with normal-tension glaucoma." 09/01/2015 - "This subanalysis of the APPEAL Korea study supports use of bimatoprost 0.01 % for previously treated patients with OAG (including normal tension glaucoma) or OHT who did not reach target IOP or were intolerant of previous treatment." 01/01/2012 - "The aim of this study was to evaluate the efficacy and safety of bimatoprost ophthalmic solution 0.03% (bimatoprost) in Japanese normal-tension glaucoma (NTG) patients with an intraocular pressure (IOP) of 18 mmHg or less. " 06/01/2006 - "The aim of this study was to investigate the effects of bimatoprost 0.03% on ocular hemodynamics in patients with normal tension glaucoma (NTG). " 01/01/2014 - "Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma."

Related Drugs and Biologics

1.	latanoprost (Xalatan)
2.	travoprost (Travatan)
3.	Timolol (Blocadren)
4.	bimatoprost (Lumigan)
5.	Synthetic Prostaglandins (Prostaglandin Analogues)
6.	Pilocarpine (Ocusert)
7.	Ophthalmic Solutions (Eye Drops)
8.	prostaglandin F2alpha receptor
9.	brimonidine (Alphagan)
10.	dorzolamide (Trusopt)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Phacoemulsification
3.	Aftercare (After-Treatment)
4.	Filtering Surgery
5.	Lasers (Laser)